Evidence map›Paper›PMID 30232597›Full record

Trial reportJournal of gastroenterology2019

The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin.

Manuele Furnari, Alessandra De Alessandri, Federico Cresta, Maria Haupt, Marta Bassi, Angela Calvi, Riccardo Haupt, Giorgia Bodini, Iftikhar Ahmed, Francesca Bagnasco and 2 more

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04674176 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

The Potential Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet

TypeinterventionalSponsorBayhealth Medical CenterRan2021 to 2022Enrolled30ConditionsWeight LossArmsRifaximin
NCT05408910 phase2 / phase3withdrawnnot on this mapstarted 2025, after this paper: background citation

Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis

TypeinterventionalSponsorWake Forest University Health SciencesRan2025 to 2025Enrolled0ConditionsCystic Fibrosis, Abdominal Pain, Small Bowel DiseaseArmsRifaximin 550 MG Oral Tablet [XIFAXAN], Placebo
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. ThePolymers · 2024
    Review
  11. Review
  12. Efficacy and Safety of a Probiotic ContainingJournal of clinical medicine · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Epidemiology of small intestinal bacterial overgrowth.World journal of gastroenterology · 2023
    Review
  20. Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Manuele FurnariDepartment of Internal Medicine, Gastroenterology Unit, Policlinico "San Martino", University of Genoa, Viale Benedetto XV, 6, 16132, Genoa, Italy. manuelefurnari@gmail.com.ORCID http://orcid.org/0000-0001-6424-079X
Alessandra De AlessandriCystic Fibrosis Center, IRCCS G. Gaslini Institute, Genoa, Italy.
Federico CrestaCystic Fibrosis Center, IRCCS G. Gaslini Institute, Genoa, Italy.
Maria HauptCystic Fibrosis Center, IRCCS G. Gaslini Institute, Genoa, Italy.
Marta BassiCystic Fibrosis Center, IRCCS G. Gaslini Institute, Genoa, Italy.
Angela CalviGastroenterology and Pediatric Endoscopy Unit, IRCCS G. Gaslini Institute, Genoa, Italy.
Riccardo HauptEpidemiology and Biostatistic Service, IRCCS G. Gaslini Institute, Genoa, Italy.
Giorgia BodiniDepartment of Internal Medicine, Gastroenterology Unit, Policlinico "San Martino", University of Genoa, Viale Benedetto XV, 6, 16132, Genoa, Italy.
Iftikhar AhmedDepartment of Gastroenterology, Aldara Hospital and Medical Centre, Riyadh, Kingdom of Saudi Arabia.
Francesca BagnascoEpidemiology and Biostatistic Service, IRCCS G. Gaslini Institute, Genoa, Italy.
Edoardo Giovanni GianniniDepartment of Internal Medicine, Gastroenterology Unit, Policlinico "San Martino", University of Genoa, Viale Benedetto XV, 6, 16132, Genoa, Italy.
Rosaria CasciaroCystic Fibrosis Center, IRCCS G. Gaslini Institute, Genoa, Italy.
Istituto Giannina Gaslini · ITUniversity of Genoa · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundScientific literature shows a high prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in patients with Cystic Fibrosis (CF). The role of SIBO in nutritional status and gastrointestinal symptoms in CF is not known. Our aim was to study epidemiology and clinical impact of SIBO while assessing the efficacy of rifaximin in eradicating SIBO in CF patients.

methodsSymptoms questionnaire and Glucose Breath Test (GBT) were given to 79 CF patients (median age 19.6 years; 9.2-36.9). Subjects with a positive GBT were enrolled in a randomized controlled trial and received rifaximin 1200 mg for 14 days or no treatment. Questionnaire and GBT were repeated 1 month after the end of treatment or 45 days after the first negative GBT.

resultsOut of 79 patients, 25 were affected by SIBO (31.6%) with a significant correlation with lower BMI, SDS-BMI (p < 0.05) and serum albumin levels (p < 0.05), independently from pancreas insufficiency. Twenty-three patients took part in the randomized trial, 13 patients (56.5%) in rifaximin group and 10 patients (43.5%) in control group. Eradication rate of SIBO was 9/10 (90%) in rifaximin group and 2/6 (33.3%) in control group (p < 0.05). In the rifaximin group, gastrointestinal symptom improvement was observed in 4/5 patients aged ≤ 14 years and in 0/5 patients aged > 14 years (p < 0.05); in 2/6 patients in the control group.

conclusionsCF patients show a high prevalence of SIBO, related to a poorer nutritional status. Rifaximin therapy is well tolerated and the results are promising in terms of efficacy in eradicating small intestinal bacterial overgrowth in CF.

Indexed as

AdolescentAdultAge FactorsBlind Loop SyndromeBody Mass IndexBreath TestsCase-Control StudiesChildCorrelation of DataCystic FibrosisFemaleHumansIntestine, SmallMaleRifaximinSerum AlbuminRifaximinSerum AlbuminCystic fibrosisHypoalbuminemiaMalabsorptionMalnutritionRifaximinSmall intestinal bacterial overgrowth

Identifiers

PMID30232597
OpenAlexW2891181335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.